Hospital de Clínicas de Porto Alegre - HCPA

Porto Alegre 90035903

0 studies enrolling now · 4 studies all time

What they study most

AB Variant Gangliosidosis GM2, Beta-Galactosidase-1 (GLB1) Deficiency, GM1 Gangliosidosis, GM1 Gangliosidosis, Type 2, GM1 Gangliosidosis, Type I, GM2 Gangliosidosis, Gaucher Disease, Type 2, Locally Advanced or Unresectable Metastatic Breast Cancer, Non-Small Cell Lung Cancer, Sandhoff Disease, Stage IV Breast Cancer, Tay-Sachs Disease

Studies at this site

• Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis — Running, not enrolling
• Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) — Running, not enrolling
• Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy — Running, not enrolling
• Natural History Study for Pediatric Patients With Early Onset of Either GM1 Gangliosidosis, GM2 Gangliosidoses, or Gaucher Disease Type 2 — Completed